Patient characteristics
| . | All patients (N = 342) . | AHCT in 2001-2010 (N = 159) . | AHCT in 2011-2020 (N = 183) . | P value∗ . | Standardized mean difference∗ . |
|---|---|---|---|---|---|
| Demographics | |||||
| Age at AHCT, median (range) | 33 (18-69) | 33 (18-68) | 33 (19-69) | .924 | 0.5% |
| Male sex, N (%) | 187 (55%) | 91 (57%) | 96 (52%) | .438 | 9.6% |
| White, non-Hispanic | 211 (62%) | 116 (73%) | 95 (52%) | <.001 | 53.8% |
| Hispanic | 60 (18%) | 25 (16%) | 35 (19%) | ||
| Asian/Pacific Islander | 35 (10%) | 12 (8%) | 23 (13%) | ||
| Black or African American | 11 (3%) | 3 (2%) | 8 (4%) | ||
| Mixed race | 25 (7%) | 3 (2%) | 22 (12%) | ||
| Histology | |||||
| Nodular sclerosis | 296 (87%) | 143 (90%) | 153 (84%) | .127 | 29.6% |
| Mixed cellularity | 22 (6%) | 7 (4%) | 15 (8%) | ||
| Lymphocyte rich | 8 (2%) | 1 (1%) | 7 (4%) | ||
| Lymphocyte depleted | 1 (<1%) | 1 (1%) | 0 (0%) | ||
| cHL NOS | 15 (4%) | 7 (4%) | 8 (4%) | ||
| Baseline disease characteristics | |||||
| Ann Arbor stage 3-4 | 184 (54%) | 82 (52%) | 102 (56%) | .508 | 8.4% |
| B symptoms | 194 (57%) | 96 (60%) | 98 (54%) | .246 | 13.8% |
| Bulky disease | 151 (44%) | 75 (47%) | 76 (42%) | .348 | 11.4% |
| Extranodal disease | 98 (29%) | 42 (26%) | 56 (31%) | .463 | 9.3% |
| Frontline therapy | |||||
| ABVD | 260 (76%) | 100 (63%) | 160 (87%) | <.001 | 62.2% |
| Stanford V | 64 (19%) | 49 (31%) | 15 (8%) | ||
| Escalated BEACOPP | 8 (2%) | 5 (3%) | 3 (2%) | ||
| Other regimen | 10 (3%) | 5 (3%) | 5 (3%) | ||
| Response to frontline therapy | |||||
| Primary refractory disease | 94 (27%) | 44 (28%) | 50 (27%) | .934 | 4.0% |
| Relapse <1 y after treatment | 122 (36%) | 58 (36%) | 64 (35%) | ||
| Relapse ≥1 y after treatment | 126 (37%) | 57 (36%) | 69 (38%) | ||
| Number of AETHERA risk factors | |||||
| 0 risk factors | 89 (26%) | 40 (25%) | 49 (27%) | .054 | 30.4% |
| 1 risk factor | 123 (36%) | 54 (34%) | 69 (38%) | ||
| 2 risk factors | 102 (30%) | 57 (36%) | 45 (25%) | ||
| 3 risk factors | 28 (8%) | 8 (5%) | 20 (11%) | ||
| Number of salvage regimens before AHCT | |||||
| 1 salvage regimen | 257 (75%) | 128 (80%) | 129 (70%) | .022 | 30.7% |
| 2 salvage regimens | 68 (20%) | 28 (18%) | 40 (22%) | ||
| 3 or more salvage regimens | 17 (5%) | 3 (2%) | 14 (8%) | ||
| Last salvage regimen before AHCT | |||||
| Platinum-based regimen | 232 (68%) | 143 (90%) | 89 (49%) | <.001 | 119.5% |
| Gemcitabine-based regimen | 35 (10%) | 8 (5%) | 27 (15%) | ||
| BV-based regimen† | 36 (11%) | 0 (0%) | 36 (20%) | ||
| PD-1 inhibitor-based regimen‡ | 27 (8%) | 0 (0%) | 27 (15%) | ||
| Other regimen | 12 (3%) | 8 (5%) | 4 (2%) | ||
| Remission status before AHCT | |||||
| CR | 178 (52%) | 67 (42%) | 111 (61%) | <.001 | 45.2% |
| PR | 144 (42%) | 76 (48%) | 68 (37%) | ||
| SD/PD | 20 (6%) | 16 (10%) | 4 (2%) |
| . | All patients (N = 342) . | AHCT in 2001-2010 (N = 159) . | AHCT in 2011-2020 (N = 183) . | P value∗ . | Standardized mean difference∗ . |
|---|---|---|---|---|---|
| Demographics | |||||
| Age at AHCT, median (range) | 33 (18-69) | 33 (18-68) | 33 (19-69) | .924 | 0.5% |
| Male sex, N (%) | 187 (55%) | 91 (57%) | 96 (52%) | .438 | 9.6% |
| White, non-Hispanic | 211 (62%) | 116 (73%) | 95 (52%) | <.001 | 53.8% |
| Hispanic | 60 (18%) | 25 (16%) | 35 (19%) | ||
| Asian/Pacific Islander | 35 (10%) | 12 (8%) | 23 (13%) | ||
| Black or African American | 11 (3%) | 3 (2%) | 8 (4%) | ||
| Mixed race | 25 (7%) | 3 (2%) | 22 (12%) | ||
| Histology | |||||
| Nodular sclerosis | 296 (87%) | 143 (90%) | 153 (84%) | .127 | 29.6% |
| Mixed cellularity | 22 (6%) | 7 (4%) | 15 (8%) | ||
| Lymphocyte rich | 8 (2%) | 1 (1%) | 7 (4%) | ||
| Lymphocyte depleted | 1 (<1%) | 1 (1%) | 0 (0%) | ||
| cHL NOS | 15 (4%) | 7 (4%) | 8 (4%) | ||
| Baseline disease characteristics | |||||
| Ann Arbor stage 3-4 | 184 (54%) | 82 (52%) | 102 (56%) | .508 | 8.4% |
| B symptoms | 194 (57%) | 96 (60%) | 98 (54%) | .246 | 13.8% |
| Bulky disease | 151 (44%) | 75 (47%) | 76 (42%) | .348 | 11.4% |
| Extranodal disease | 98 (29%) | 42 (26%) | 56 (31%) | .463 | 9.3% |
| Frontline therapy | |||||
| ABVD | 260 (76%) | 100 (63%) | 160 (87%) | <.001 | 62.2% |
| Stanford V | 64 (19%) | 49 (31%) | 15 (8%) | ||
| Escalated BEACOPP | 8 (2%) | 5 (3%) | 3 (2%) | ||
| Other regimen | 10 (3%) | 5 (3%) | 5 (3%) | ||
| Response to frontline therapy | |||||
| Primary refractory disease | 94 (27%) | 44 (28%) | 50 (27%) | .934 | 4.0% |
| Relapse <1 y after treatment | 122 (36%) | 58 (36%) | 64 (35%) | ||
| Relapse ≥1 y after treatment | 126 (37%) | 57 (36%) | 69 (38%) | ||
| Number of AETHERA risk factors | |||||
| 0 risk factors | 89 (26%) | 40 (25%) | 49 (27%) | .054 | 30.4% |
| 1 risk factor | 123 (36%) | 54 (34%) | 69 (38%) | ||
| 2 risk factors | 102 (30%) | 57 (36%) | 45 (25%) | ||
| 3 risk factors | 28 (8%) | 8 (5%) | 20 (11%) | ||
| Number of salvage regimens before AHCT | |||||
| 1 salvage regimen | 257 (75%) | 128 (80%) | 129 (70%) | .022 | 30.7% |
| 2 salvage regimens | 68 (20%) | 28 (18%) | 40 (22%) | ||
| 3 or more salvage regimens | 17 (5%) | 3 (2%) | 14 (8%) | ||
| Last salvage regimen before AHCT | |||||
| Platinum-based regimen | 232 (68%) | 143 (90%) | 89 (49%) | <.001 | 119.5% |
| Gemcitabine-based regimen | 35 (10%) | 8 (5%) | 27 (15%) | ||
| BV-based regimen† | 36 (11%) | 0 (0%) | 36 (20%) | ||
| PD-1 inhibitor-based regimen‡ | 27 (8%) | 0 (0%) | 27 (15%) | ||
| Other regimen | 12 (3%) | 8 (5%) | 4 (2%) | ||
| Remission status before AHCT | |||||
| CR | 178 (52%) | 67 (42%) | 111 (61%) | <.001 | 45.2% |
| PR | 144 (42%) | 76 (48%) | 68 (37%) | ||
| SD/PD | 20 (6%) | 16 (10%) | 4 (2%) |
Bold values denote statistical significance at the P < .05 level.
BEACOPP, bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone; N, number of patients; NOS, not otherwise specified.
P values and standardized mean difference values indicate a comparison between patients undergoing AHCT in 2001 to 2010 vs 2011 to 2020.
Includes BV alone or in combination with chemotherapy (eg, BV/bendamustine, BV-ICE).
Includes PD-1 inhibitor alone or in combination with other agents (eg, pembrolizumab, nivolumab/BV).